Pagetoid reticulosis after radiotherapy of primary cutaneous anaplastic large-cell lymphoma. 2010

Stephen E Mercer, and Claudia I Vidal, and Sarah E Grummer, and James A Strauchen, and Marsha L Gordon, and Miriam B Birge
Division of Dermatopathology, Mount Sinai School of Medicine, New York, NY 10029, USA. stephen.mercer@mssm.edu

We describe a 60-year-old man with a history of primary cutaneous anaplastic large cell lymphoma on the chest, who presented with a new scaly red plaque on the same site 11 years after radiation therapy. Histological examination revealed a dense epidermotropic infiltrate of atypical mononuclear cells consistent with pagetoid reticulosis. Immunohistochemistry revealed the infiltrate to be CD4, CD8, and CD30. Remarkably, all the atypical cells were strongly CD30, and furthermore, the CD30 cells were found exclusively in the epidermis. In the initial cutaneous anaplastic large cell lymphoma lesion, the CD4, CD8, and focally CD30 atypical cells were well confined within the dermis with no epidermal component. To our knowledge, the present case seems to be the first description of pagetoid reticulosis presenting at the site of a previously treated dermal anaplastic large cell lymphoma. This case also represents an extreme presentation of epidermotropism and CD30 expression in pagetoid reticulosis.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012878 Skin Neoplasms Tumors or cancer of the SKIN. Cancer of Skin,Skin Cancer,Cancer of the Skin,Neoplasms, Skin,Cancer, Skin,Cancers, Skin,Neoplasm, Skin,Skin Cancers,Skin Neoplasm
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015703 Antigens, CD Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation. CD Antigen,Cluster of Differentiation Antigen,Cluster of Differentiation Marker,Differentiation Antigens, Leukocyte, Human,Leukocyte Differentiation Antigens, Human,Cluster of Differentiation Antigens,Cluster of Differentiation Markers,Antigen Cluster, Differentiation,Antigen, CD,CD Antigens,Differentiation Antigen Cluster,Differentiation Marker Cluster,Marker Cluster, Differentiation
D016609 Neoplasms, Second Primary Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause. Neoplasms, Metachronous,Neoplasms, Metachronous Second Primary,Neoplasms, Therapy-Related,Neoplasms, Treatment-Related,Second Malignancy,Second Neoplasm,Second Primary Neoplasms,Therapy-Associated Neoplasms,Therapy-Related Cancer,Treatment-Associated Neoplasms,Treatment-Related Cancer,Cancer, Second Primary,Metachronous Neoplasms,Metachronous Second Primary Neoplasms,Neoplasms, Therapy-Associated,Neoplasms, Treatment-Associated,Second Cancer,Second Primary Neoplasms, Metachronous,Therapy-Associated Cancer,Therapy-Related Neoplasms,Treatment-Associated Cancer,Treatment-Related Neoplasms,Cancer, Second,Cancer, Therapy-Associated,Cancer, Therapy-Related,Cancer, Treatment-Associated,Cancer, Treatment-Related,Cancers, Second,Cancers, Second Primary,Cancers, Therapy-Associated,Cancers, Therapy-Related,Cancers, Treatment-Associated,Cancers, Treatment-Related,Malignancies, Second,Malignancy, Second,Metachronous Neoplasm,Neoplasm, Metachronous,Neoplasm, Second,Neoplasm, Second Primary,Neoplasm, Therapy-Associated,Neoplasm, Therapy-Related,Neoplasm, Treatment-Associated,Neoplasm, Treatment-Related,Neoplasms, Second,Neoplasms, Therapy Associated,Neoplasms, Therapy Related,Neoplasms, Treatment Associated,Neoplasms, Treatment Related,Second Cancers,Second Malignancies,Second Neoplasms,Second Primary Cancer,Second Primary Cancers,Second Primary Neoplasm,Therapy Associated Cancer,Therapy Associated Neoplasms,Therapy Related Cancer,Therapy Related Neoplasms,Therapy-Associated Cancers,Therapy-Associated Neoplasm,Therapy-Related Cancers,Therapy-Related Neoplasm,Treatment Associated Cancer,Treatment Associated Neoplasms,Treatment Related Cancer,Treatment Related Neoplasms,Treatment-Associated Cancers,Treatment-Associated Neoplasm,Treatment-Related Cancers,Treatment-Related Neoplasm
D017728 Lymphoma, Large-Cell, Anaplastic A systemic, large-cell, non-Hodgkin, malignant lymphoma characterized by cells with pleomorphic appearance and expressing the CD30 ANTIGEN. These so-called "hallmark" cells have lobulated and indented nuclei. This lymphoma is often mistaken for metastatic carcinoma and MALIGNANT HISTIOCYTOSIS. Anaplastic Large-Cell Lymphoma,CD30-Positive Anaplastic Large-Cell Lymphoma,Lymphoma, Large-Cell, Ki-1,CD30+ Anaplastic Large-Cell Lymphoma,Ki-1 Lymphoma,Systemic Anaplastic Large-Cell Lymphoma,Anaplastic Large Cell Lymphoma,Anaplastic Large-Cell Lymphomas,CD30 Positive Anaplastic Large Cell Lymphoma,CD30+ Anaplastic Large Cell Lymphoma,Ki 1 Lymphoma,Ki-1 Lymphomas,Large-Cell Lymphoma, Anaplastic,Large-Cell Lymphomas, Anaplastic,Lymphoma, Anaplastic Large-Cell,Lymphoma, Ki-1,Lymphomas, Anaplastic Large-Cell,Lymphomas, Ki-1,Systemic Anaplastic Large Cell Lymphoma
D056267 Pagetoid Reticulosis A distinct variant of mycosis fungoides characterized by the presence of localized patches or plaques with an intraepidermal proliferation of neoplastic cells. Ketron-Goodman Disease,Woringer-Kolopp Disease,Woringer Kolopp Disease,Disease, Ketron-Goodman,Disease, Woringer Kolopp,Disease, Woringer-Kolopp,Ketron Goodman Disease,Kolopp Disease, Woringer,Pagetoid Reticuloses,Reticuloses, Pagetoid,Reticulosis, Pagetoid

Related Publications

Stephen E Mercer, and Claudia I Vidal, and Sarah E Grummer, and James A Strauchen, and Marsha L Gordon, and Miriam B Birge
January 2010, Journal of cutaneous and aesthetic surgery,
Stephen E Mercer, and Claudia I Vidal, and Sarah E Grummer, and James A Strauchen, and Marsha L Gordon, and Miriam B Birge
June 2017, Journal of cutaneous pathology,
Stephen E Mercer, and Claudia I Vidal, and Sarah E Grummer, and James A Strauchen, and Marsha L Gordon, and Miriam B Birge
October 2010, Pediatric hematology and oncology,
Stephen E Mercer, and Claudia I Vidal, and Sarah E Grummer, and James A Strauchen, and Marsha L Gordon, and Miriam B Birge
November 2010, Dermatology online journal,
Stephen E Mercer, and Claudia I Vidal, and Sarah E Grummer, and James A Strauchen, and Marsha L Gordon, and Miriam B Birge
January 2019, Dermatopathology (Basel, Switzerland),
Stephen E Mercer, and Claudia I Vidal, and Sarah E Grummer, and James A Strauchen, and Marsha L Gordon, and Miriam B Birge
October 2013, American journal of clinical oncology,
Stephen E Mercer, and Claudia I Vidal, and Sarah E Grummer, and James A Strauchen, and Marsha L Gordon, and Miriam B Birge
May 1991, The Journal of investigative dermatology,
Stephen E Mercer, and Claudia I Vidal, and Sarah E Grummer, and James A Strauchen, and Marsha L Gordon, and Miriam B Birge
April 2007, Actas dermo-sifiliograficas,
Stephen E Mercer, and Claudia I Vidal, and Sarah E Grummer, and James A Strauchen, and Marsha L Gordon, and Miriam B Birge
May 2012, The American Journal of dermatopathology,
Stephen E Mercer, and Claudia I Vidal, and Sarah E Grummer, and James A Strauchen, and Marsha L Gordon, and Miriam B Birge
October 2019, The American Journal of dermatopathology,
Copied contents to your clipboard!